Frazier Life Sciences Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-470,338
| Closed | -$7.81M | – | 50 |
|
|
2025
Q1 | $7.81M | Hold |
470,338
| – | – | 0.36% | 34 |
|
|
2024
Q4 | $8.63M | Hold |
470,338
| – | – | 0.36% | 38 |
|
|
2024
Q3 | $7.23M | Hold |
470,338
| – | – | 0.29% | 45 |
|
|
2024
Q2 | $7.64M | Hold |
470,338
| – | – | 0.36% | 40 |
|
|
2024
Q1 | $8.7M | Sell |
470,338
-260,579
| -36% | -$4.82M | 0.37% | 42 |
|
|
2023
Q4 | $22.9M | Buy |
730,917
+100,020
| +16% | +$3.13M | 1.22% | 23 |
|
|
2023
Q3 | $13.1M | Sell |
630,897
-226,441
| -26% | -$4.72M | 0.87% | 29 |
|
|
2023
Q2 | $20.5M | Hold |
857,338
| – | – | 1.23% | 20 |
|
|
2023
Q1 | $16.1M | Hold |
857,338
| – | – | 1.17% | 23 |
|
|
2022
Q4 | $13.6M | Hold |
857,338
| – | – | 0.85% | 23 |
|
|
2022
Q3 | $14M | Buy |
+857,338
| New | +$14M | 1.08% | 22 |
|